MarginsXMarginsX
Home › Markets › RGBPP

Regen BioPharma Inc (RGBPP)

RGBPP is quoted over the counter, not listed on an exchange. Regen BioPharma Inc files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.

Close · November 16, 2026
$0.0007
-15.7% on the day
1-year return
-98.8%
Market cap
Another share class (preferred); the SEC share count is the common shares, so no cap for this line
P/E and P/S
Needs a market cap · Needs a market cap
On trailing twelve months to June 30, 2026 (10-Q)

Closes: Yahoo Finance daily closes, last bar 2026-11-16.

Profile

FieldValue
TickerRGBPP, quoted over the counter
SEC CIK0001589150
OTC Markets tierOTCID (price source, 2026-11-13)
SEC industry codePharmaceutical Preparations
Business addressLa Mesa, CA
Incorporated inNV

Warning signs

Cash runway
0.0 months
$239 cash at June 30, 2026
Share count, 1 year
+5209.1%
2025-06-30 to 2026-08-12 · +24672.2% over 3 years
Going-concern doubt
Yes
10-Q filed August 17, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Without additional funding, there is substantial doubt about the Company's ability to continue as a going concern for the twelve months from the date of these financial statements."
10-Q 2026-08-17
Cash and burn$239 cash; operating cash flow -$111K a quarter.Report 2026-06-30
Shares outstanding1,675,277,503 (2026-08-12); 31,554,704 a year earlier; 3,381,366 three years earlier. 3y figure adjusted for splits (2-for-1 overall).Cover page 2026-08-12
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorBCRG Group, Irvine, California, United States; changed auditors 2 times in 24 months8-K 4.01 2026-07-15
Late filings, 12 months1 NT noticeNT 10-Q 2026-08-13
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-06-30
$59K-$638K-$24K$239$1.5M$237K10-Q 2026-08-17
Q2 2026
2026-03-31
$59K$992K-$63K$271$1.6M$237K10-Q 2026-05-14
Q1 2026
2025-12-31
$59K-$968K-$198K$5K$1.9M$237K10-Q 2026-02-13
Q4 2025
2025-09-30
$59K-$572K-$160K$70K$2.0M$237K10-K 2025-12-30
Q3 2025
2025-06-30
$59K-$167K-$56K$2K$1.5M$237K10-Q 2026-08-17
Q2 2025
2025-03-31
$59K-$19K-$101K$2K$968K$237K10-Q 2026-05-14
Q1 2025
2024-12-31
$59K-$515K-$66K$135$852K$209K10-Q 2026-02-13
Q4 2024
2024-09-30
$59K-$271K-$207K$716$1.3M$182K10-K 2025-12-30

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document253G12025-12-05
Latest annual report10-K2025-12-30
Latest quarterly / interim10-Q2026-08-17
Latest current report8-K2026-11-02

Source: SEC EDGAR submissions feed, 263 recent filings. All filings on EDGAR.

The full dossier has every filing, quarterly and annual financials, the health record and a price chart.

Open the full dossier